AKT1 and colorectal carcinoma: This dual inhibitor was shown to block AKT-S6K1 activation and inhibit human tumor cell proliferation [15].Although the effect of AT7867 on human CRC viability was examined by Grimshaw et al [15], this effect remains to be fully characterized.